Loading
Established PD-1 blockade in relapsed Hodgkin lymphoma with ~70% response rates and seeded the frontline nivolumab-AVD idea.
CheckMate 205, trial NCT02181738 sponsored by Bristol Myers Squibb and reported in 2016, established PD-1 blockade with nivolumab in relapsed or refractory classical Hodgkin lymphoma after autologous transplant, with responses in about seventy percent of patients, and seeded the frontline nivolumab-AVD idea. Across 243 patients in cohorts A to C the response rate was 69 percent with complete responses in 16 percent and durable progression-free intervals, leading to accelerated approval in May 2016, while cohort D tested nivolumab-AVD in the frontline with very high complete response rates, the basis for SWOG S1826. OnCo links it to Hodgkin lymphoma, nivolumab and the pairing of PD-1 blockade with AVD chemotherapy. Whether PD-1 blockade can replace chemotherapy entirely in some patients is the question its cohort D opened.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Nivolumab, like pembrolizumab, is a standard for relapsed Hodgkin lymphoma after transplant, and the activity seen here led to its testing in first-line therapy (S1826).
One of the most cited trial reports Europe PMC returns for Brentuximab vedotin in Hodgkin lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial, CheckMate 205: nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous transplant failure, extended follow-up, Hodgkin lymphoma, Nivolumab.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma, Immune checkpoint inhibitors.
Shares PD-1 blockade + AVD chemotherapy, Hodgkin lymphoma, Nivolumab, Immune checkpoint inhibitors.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares PD-1 blockade + AVD chemotherapy, Hodgkin lymphoma, Nivolumab, Immune checkpoint inhibitors.